Route of Administration for Biological Therapy
Biological therapy is predominantly administered via subcutaneous injection, though intravenous infusion is also commonly used depending on the specific agent and clinical indication. 1
Primary Administration Routes
Subcutaneous (SC) Administration
The subcutaneous route is the most frequently recommended method for biologic therapy delivery:
- Guselkumab: 100 mg by self-administered subcutaneous injection at week 0, week 4, and every 8 weeks thereafter 1
- Tildrakizumab: 100 mg given by in-office physician-administered subcutaneous injection at week 0, week 4, and every 12 weeks thereafter 1
- Adalimumab: Administered subcutaneously for psoriasis and inflammatory bowel disease 1, 2
- Etanercept: Given subcutaneously for psoriatic conditions 2
- Ustekinumab: Delivered via subcutaneous injection 2
Intravenous (IV) Administration
Certain biologics require intravenous infusion:
- Rituximab: Administered only as an intravenous infusion, never as an IV push or bolus 3
- Infliximab: Given intravenously, particularly for severe disease or when other agents have failed 2, 4
Key Considerations for Route Selection
Patient Preference Factors
Route of administration significantly impacts patient acceptance and adherence 1:
- Subcutaneous advantages: Self-administration at home, less frequent healthcare visits, reduced resource utilization 5
- Dosing schedule considerations: Biologics with less frequent dosing (every 8-12 weeks) may be preferred by patients 1
- Patient autonomy: Self-administered subcutaneous injections provide greater flexibility and independence 5
Clinical Efficacy Considerations
Recent evidence demonstrates comparable effectiveness between routes 6:
- No difference in clinical remission rates between IV and SC administration for vedolizumab and infliximab in inflammatory bowel disease 6
- Equivalent safety and efficacy profiles for many biologics regardless of administration route 7, 5
Practical Administration Details
For subcutaneous biologics 1:
- Can be self-administered or given by healthcare providers
- Typical injection sites include abdomen, thigh, or upper arm
- Volumes generally limited to accommodate subcutaneous tissue capacity
For intravenous biologics 3:
- Must be administered by healthcare professionals with appropriate medical support
- Requires infusion monitoring for severe reactions
- Initial infusion rates start at 50 mg/hr, increasing incrementally to maximum 400 mg/hr based on tolerance
- Premedication required before each infusion
Common Pitfalls to Avoid
- Never administer IV biologics as a push or bolus - only as controlled infusion 3
- Do not assume all biologics can be self-administered - some require healthcare setting administration, particularly in oncology 5
- Avoid switching routes without considering pharmacokinetic differences - absorption profiles differ between SC and IV administration 5, 8